Center for Rhinology and Allergology, Wiesbaden, Germany.
Department of Skin Diseases, Outpatient Clinic for Allergology, Occupational Dermatology and Environmental Medicine, Münster University Hospital, Münster, Germany.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2066424. doi: 10.1080/21645515.2022.2066424. Epub 2022 Jun 15.
Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair® is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair® in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.
舌下免疫疗法（SLIT）是一种耐受良好、安全且有效的治疗变应性鼻炎（AR）的方法。Oralair® 是一种含有五种主要草花粉过敏原的五草花粉 SLIT 片剂，这些过敏原是导致因草花粉过敏引起的季节性 AR 的罪魁祸首。推荐在预季节性方案中使用，在花粉季节开始前大约 4 个月开始每日治疗，然后在整个季节中持续每日治疗；治疗应持续 3-5 年。Oralair® 在花粉诱导的 AR 患者中的临床疗效和安全性已在全面的随机对照临床试验临床开发计划中得到证实。在随后的观察性研究中，停止治疗后仍能持续有效，且患者的依从性、生活质量、获益和满意度水平良好，证实了其有效性。越来越多的证据表明，它有助于降低发生或延缓发展变应性哮喘的风险。
